IGM Biosciences is again cutting staff as it scraps an autoimmune-drug trial after failing to achieve the desired results.

IGM Biosciences (NASDAQ:IGMS) announced that it is currently evaluating internal options as well as potential strategic alternatives. Under these changes, it will halt further development of imvotamab ...

IGM Biosciences has decided to halt development of imvotamab and IGM-2644, two IgM-based bispecific antibody T cell engagers for autoimmune diseases, and cut its staff by 73%. The biotechnology ...

IGM Biosciences, Inc. (Nasdaq: IGMS), a biotechnology company committed to developing and delivering medicines to treat patients with autoimmune and inflammatory diseases, today announced a strategic ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Lifordi Immunotherapeutics, Inc., a biotech company developing antibody-drug conjugates (ADCs) for the treatment of ...

Johnson & Johnson has won Food and Drug Administration priority review for its application seeking approval of nipocalimab in certain patients with generalized myasthenia gravis.

Nurix Therapeutics (NRIX) leads in targeted protein modulation with its DELigase platform, developing BTK degraders like ...

Under the deal, Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform. The Chinese company is set to receive an undisclosed upfront payment, as ...

A German research team’s discoveries about autoimmune diseases are opening up new possibilities for patients with lupus and ...

Human aging is a complex physiological process that is accompanied by the onset of various aging-related disorders, including ...

Elvis Presley died in 1977 at 42 years old. His autopsy report was sealed for 50 years and will be released in 2027. Various ...